BioTech Health X
  • BioTech News
  • BioTech CEO Interviews
  • Contact Us
Archives
  • October 2026
  • September 2026
  • August 2026
  • July 2026
  • June 2026
  • May 2026
  • April 2026
  • March 2026
  • February 2026
  • January 2026
  • December 2025
  • November 2025
  • October 2025
  • September 2025
  • August 2025
  • July 2025
  • June 2025
  • May 2025
  • March 2025
  • February 2025
  • January 2025
  • December 2024
  • November 2024
  • September 2024
  • August 2024
  • July 2024
  • May 2024
  • April 2024
  • December 2023
  • October 2023
  • August 2023
  • September 2022
  • August 2022
  • July 2022
  • June 2022
  • May 2022
  • April 2022
  • March 2022
  • February 2022
  • December 2021
  • November 2021
  • September 2021
  • August 2021
  • July 2021
  • June 2021
  • May 2021
  • April 2021
BioTech Health X
  • BioTech News
  • BioTech CEO Interviews
  • Contact Us
Subscribe

Browsing Tag

Capricor Therapeutics

3 posts

Capricor Therapeutics, Inc. (Nasdaq: CAPR) is a clinical-stage biotechnology company that is focused on the discovery, development, and commercialization of first-in-class cell and exosome-based therapeutics for the treatment and prevention of diseases.

Capricor’s innovative technology builds upon a large body of scientific research and enables them to approach the treatment of diseases in novel ways. The company is a leader in the field of exosome science.

Capricor’s lead candidate is CAP-1002. This “off-the-shelf” cardiac cell therapy is currently in clinical development for the treatment of Duchenne muscular dystrophy (DMD) and COVID-19.

CAP-1002 consists of allogeneic cardiosphere-derived cells, or CDCs, a unique population of cells that have been shown to exert potent immunomodulatory activity, which alters the immune system’s activity to stimulate cellular regeneration. CDCs have been the subject of over 100 peer-reviewed scientific publications. They have been administered to approximately 200+ human subjects throughout multiple clinical trials.

Capricor studies have been showing that exosome technology is significantly active in several disease models. The company is developing its exosome technologies as a next generation platform in a variety of diseases.

BioTech CEO InterviewsPioneering Cell & Exosome Therapies for Rare Diseases | Capricor Therapeutics Interview with Dr. Linda Marbán and AJ Bergmann

  • BioTech Health X
  • August 10, 2024
Join us on BioTech Health X as we sit down with Dr. Linda Marbán, CEO, and AJ Bergmann,…
0 Shares
0
0
0
0
0
0
0
Capricor Therapeutics To Present Final HOPE-2 Trial CAP-1002 Data for Late-Stage Duchenne Muscular Dystrophy (DMD)

Biotech NewsCapricor Therapeutics To Present Final HOPE-2 Trial CAP-1002 Data for Late-Stage Duchenne Muscular Dystrophy (DMD)

  • BioTech Health X
  • September 3, 2021
Capricor Therapeutics Announces HOPE-2 Trial Data Presentation On September 2nd, Capricor Therapeutics (NASDAQ: CAPR) announced an upcoming company…
0 Shares
0
0
0
0
0
0
0
Capricor CEO to Present at American Society of Gene and Cell Therapy Annual Meeting Ahead of Q1 Earnings Update

Biotech NewsCapricor CEO to Present at American Society of Gene and Cell Therapy Annual Meeting Ahead of Q1 Earnings Update

  • BioTech Health X
  • May 12, 2021
May 13 is a busy day for biotechnology company Capricor Therapeutics (NASDAQ: CAPR). The company which focuses on…
0 Shares
0
0
0
0
0
0
0
Recent Posts
  • 5 Best Micro Cap Healthcare Stocks to Watch Today
  • CorMedix (CRMD) Posts 157% Revenue Growth and $26M in Profit but There’s an Acquisition Twist
  • Mirum Pharmaceuticals (MIRM) Flexes 46% LIVMARLI Sales Growth
  • ADMA Biologics (ADMA) Delivers 26% ASCENIV Growth but Its Other Numbers Tell a Different Story
  • Rigel Pharmaceuticals (RIGL) Turns 14% Product Sales Growth Into a $17.3M Profit
Featured Posts
    • October 18, 2026
    5 Best Micro Cap Healthcare Stocks to Watch Today
    • October 17, 2026
    CorMedix (CRMD) Posts 157% Revenue Growth and $26M in Profit but There’s an Acquisition Twist
    • October 17, 2026
    Mirum Pharmaceuticals (MIRM) Flexes 46% LIVMARLI Sales Growth
    • October 17, 2026
    ADMA Biologics (ADMA) Delivers 26% ASCENIV Growth but Its Other Numbers Tell a Different Story
    • October 17, 2026
    Rigel Pharmaceuticals (RIGL) Turns 14% Product Sales Growth Into a $17.3M Profit
Recent Posts
  • Progyny (PGNY) Generates $50.4M in Quarterly Cash Flow
    • October 17, 2026
  • Nuvation Bio (NUVB) Posts 25% Drug Sales Growth
    • October 17, 2026
  • Top 6 Small-Cap Healthcare Stocks to Buy Right Now
    • October 17, 2026
Categories
  • BioTech CEO Interviews (9)
  • Biotech Info (6)
  • Biotech News (1,126)
  • Uncategorized (2)
Author
Hello, I’m
BioTech Health X
Follow
BioTech Health X
Designed & Developed by BioTech Health X
  • About BioTech Health X
  • List of Modern Life Science Technologies
  • Biotechnology Company Directory – List of Major Biotech Companies
  • Contact Us
  • Privacy Policy

Subscribe to
Our Updates

Back to top